FDA
-
-
-
-
-
-
-
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
-
-
-
-
-
-
-
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
-
-
-
-
-
-
-
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
-
-
-
-
-
-
-
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Ba
-
-
-
-
-
-
-
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

